THERAVANCE PATENT

Vection/tmdt A/\$5

Patent Attorney Docket AMI-087-R

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231 at the facsimile number indicated below.

number indicated below.

Dated: 4 | 18,2003 | Facsimile Number: (703) 872-9306 (before final)

By: Barbara Bryant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	
Burton G. Christensen et al.)	Group Art Unit: 1653
Application No.: 09/776,466	ý	Examiner: D. Lukton
)	Examiner: D. Lukton
Filed: February 2, 2001)	
For: Glycopeptide Derivatives	j	

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Dear Sir:

Applicants respectfully submit the following amendments and remarks in response to the Restriction Requirement mailed on April 4, 2003, for which a one month response period was designated. Therefore, this response is considered timely filed on or before May 4, 2003.

Pursuant to the Official Gazette Notice dated February 25, 2003, entitled AMENDMENTS IN A REVISED FORMAT NOW PERMITTED, Applicants respectfully request that the provisions of 37 C.F.R. §1.121 be waived for the present amendments since these amendments are believed to comply with the revised amendment format set forth the OG announcement.

Application Serial No.: 09/776,466
Attorney Docket No. P-087-R

page 1 of 17